Mirae Asset Global Investments Co. Ltd. Buys 126,572 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 126,572 shares of the biopharmaceutical company’s stock, valued at approximately $95,976,000. Mirae Asset Global Investments Co. Ltd. owned 0.12% of Regeneron Pharmaceuticals at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Vise Technologies Inc. raised its stake in shares of Regeneron Pharmaceuticals by 22.4% during the third quarter. Vise Technologies Inc. now owns 2,622 shares of the biopharmaceutical company’s stock valued at $1,989,000 after acquiring an additional 480 shares in the last quarter. Grandfield & Dodd LLC grew its stake in Regeneron Pharmaceuticals by 1.3% in the third quarter. Grandfield & Dodd LLC now owns 37,098 shares of the biopharmaceutical company’s stock worth $28,130,000 after purchasing an additional 470 shares in the last quarter. Summit Global Investments increased its holdings in Regeneron Pharmaceuticals by 2.2% during the 3rd quarter. Summit Global Investments now owns 7,670 shares of the biopharmaceutical company’s stock worth $5,816,000 after purchasing an additional 164 shares during the period. Invera Wealth Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 59.6% during the 3rd quarter. Invera Wealth Advisors LLC now owns 787 shares of the biopharmaceutical company’s stock worth $597,000 after purchasing an additional 294 shares during the period. Finally, MGO One Seven LLC raised its position in Regeneron Pharmaceuticals by 49.0% during the 3rd quarter. MGO One Seven LLC now owns 1,389 shares of the biopharmaceutical company’s stock valued at $1,053,000 after purchasing an additional 457 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 13.3%

Shares of Regeneron Pharmaceuticals stock opened at $927.89 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $591.52 and a 12-month high of $935.35. The firm’s 50 day simple moving average is $793.30 and its two-hundred day simple moving average is $738.05. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $95.54 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period in the previous year, the company earned $11.83 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director owned 603 shares of the company’s stock, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock worth $6,506,845 in the last 90 days. 6.97% of the stock is owned by company insiders.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Analysts Set New Price Targets

Several equities research analysts have weighed in on REGN shares. Robert W. Baird upped their target price on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. The Goldman Sachs Group increased their target price on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, UBS Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the company from $660.00 to $978.00 in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $850.83.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.